OUR PIPELINE

SAN903

Saniona Icon blue

SAN903

Precise modulation of ion channels for inflammation and fibrosis

SAN903 is a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCa3.1. It is currently in preclinical development for the treatment of rare inflammatory and fibrotic disorders.

How SAN903 works

SAN903

IMMUNE CELLS & FIBROBLASTS

Tesomet Infographics

NO cytokine/collagen production

NO cell division and migration

The calcium-activated potassium ion channel, KCa3.1, is important for activation of immune cells in the brain and other tissues, and it is also involved in the abnormal production of connective tissue that can lead to fibrosis in chronic diseases. Saniona leveraged its ion channel drug discovery engine to precisely target KCa3.1, resulting in a so-called “weak activation” that has been shown in preclinical models to produce efficacy without the side effects of so-called “strong activation.”

SAN903 STATUS

SAN903 is expected to enter the clinic in the second half of 2022.